Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate
BackgroundSPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment of cognitive function was a predefined safety outco...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 January 2018
|
| In: |
CNS drugs
Year: 2018, Jahrgang: 32, Heft: 1, Pages: 85-95 |
| ISSN: | 1179-1934 |
| DOI: | 10.1007/s40263-017-0487-z |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/s40263-017-0487-z
|
| Verfasserangaben: | David R. Coghill, Tobias Banaschewski, Caleb Bliss, Brigitte Robertson, Alessandro Zuddas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1666316334 | ||
| 003 | DE-627 | ||
| 005 | 20230427154403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190527s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40263-017-0487-z |2 doi | |
| 035 | |a (DE-627)1666316334 | ||
| 035 | |a (DE-599)KXP1666316334 | ||
| 035 | |a (OCoLC)1341225458 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Coghill, David |e VerfasserIn |0 (DE-588)1056994487 |0 (DE-627)795032463 |0 (DE-576)314253319 |4 aut | |
| 245 | 1 | 0 | |a Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate |c David R. Coghill, Tobias Banaschewski, Caleb Bliss, Brigitte Robertson, Alessandro Zuddas |
| 264 | 1 | |c 30 January 2018 | |
| 300 | |b Diagramme | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.05.2019 | ||
| 520 | |a BackgroundSPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment of cognitive function was a predefined safety outcome in SPD489-404.ObjectiveThe objective of this study was to assess cognitive function over 2 years in study SPD489-404, using the Cambridge Neuropsychological Test Automated Battery (CANTAB).MethodsParticipants aged 6-17 years received dose-optimised open-label lisdexamfetamine dimesylate (30, 50 or 70 mg/day) for 104 weeks. Cognition was assessed using four CANTAB tasks; Delayed Matching to Sample (DMS), Spatial Working Memory (SWM), Stop Signal Task (SST) and Reaction Time (RTI). Key and additional variables were pre-specified for each CANTAB task; groupwise mean percentage changes in key variables from baseline of > 5% were considered potentially clinically significant.ResultsAll 314 enrolled participants received lisdexamfetamine dimesylate and were included in the safety population, and 191 (60.8%) completed the study. No potentially clinically significant deteriorations from baseline were observed in any key CANTAB variable over the 2 years of the study. Based on predefined thresholds, potentially clinically significant improvements from baseline were observed at 6 months (DMS median reaction time, mean per cent change, − 6.6%; SWM total between-search errors, − 22.8%; SST stop signal reaction time, -18.9%), and at the last on-treatment assessment (DMS median reaction time, − 6.5%; SWM total between-search errors, − 32.6%; SST stop signal reaction time, − 25.7%).ConclusionsLisdexamfetamine dimesylate treatment for 2 years was not associated with deterioration of cognitive function in children and adolescents with attention-deficit/hyperactivity disorder. Although improvements in some cognitive measures were observed, lack of a control group makes interpretation of the findings difficult. Further studies of the impact of stimulants on cognition are required.ClinicalTrials.gov identifierNCT01328756. | ||
| 700 | 1 | |a Banaschewski, Tobias |d 1961- |e VerfasserIn |0 (DE-588)115856110 |0 (DE-627)507227301 |0 (DE-576)178364703 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS drugs |d Berlin [u.a.] : Springer, 1994 |g 32(2018), 1, Seite 85-95 |h Online-Ressource |w (DE-627)327645172 |w (DE-600)2043806-0 |w (DE-576)273880845 |x 1179-1934 |7 nnas |a Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate |
| 773 | 1 | 8 | |g volume:32 |g year:2018 |g number:1 |g pages:85-95 |g extent:11 |a Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40263-017-0487-z |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190527 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 115856110 |a Banaschewski, Tobias |m 115856110:Banaschewski, Tobias |d 60000 |e 60000PB115856110 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1666316334 |e 347973166X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 27.05.2019"],"physDesc":[{"extent":"11 S.","noteIll":"Diagramme"}],"id":{"eki":["1666316334"],"doi":["10.1007/s40263-017-0487-z"]},"title":[{"title_sort":"Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate","title":"Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylate"}],"language":["eng"],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"30 January 2018"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"language":["eng"],"origin":[{"dateIssuedKey":"1994","publisherPlace":"Berlin [u.a.] ; Auckland [u.a.]","dateIssuedDisp":"1994-","publisher":"Springer ; Adis Intern."}],"pubHistory":["1.1994 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"CNS drugs","title":"CNS drugs","subtitle":"evaluations of drug therapy in the management of psychiatric and neurological disease"}],"note":["Gesehen am 23.04.14"],"recId":"327645172","part":{"pages":"85-95","year":"2018","volume":"32","text":"32(2018), 1, Seite 85-95","extent":"11","issue":"1"},"disp":"Cognitive function of children and adolescents with attention-deficit/hyperactivity disorder in a 2-year open-label study of lisdexamfetamine dimesylateCNS drugs","type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["327645172"],"issn":["1179-1934"],"zdb":["2043806-0"]}}],"name":{"displayForm":["David R. Coghill, Tobias Banaschewski, Caleb Bliss, Brigitte Robertson, Alessandro Zuddas"]},"person":[{"given":"David","family":"Coghill","display":"Coghill, David","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Banaschewski","given":"Tobias","display":"Banaschewski, Tobias","roleDisplay":"VerfasserIn","role":"aut"}],"recId":"1666316334"} | ||
| SRT | |a COGHILLDAVCOGNITIVEF3020 | ||